Skip to search formSkip to main contentSkip to account menu

GLP-1 Mimetics

Known as: GLP-1 Analogue 
Any of the analogues of the endogenous gastrointestinal hormone glucagon-like peptide-1 (GLP-1) with antihyperglycemic activity. GLP-1 mimetics mimic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed…
BackgroundIncretin-based therapies are used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. We investigated the… 
Highly Cited
2016
Highly Cited
2016
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
AbstractBackgroundLiraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes… 
Highly Cited
2015
Highly Cited
2015
Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice
Aims/hypothesisGlucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonism, used in the treatment of type 2 diabetes, has recently… 
Highly Cited
2013
Highly Cited
2013
Neuroprotective Effects of Liraglutide for Stroke Model of Rats
The number of diabetes mellitus (DM) patients is increasing, and stroke is deeply associated with DM. Recently, neuroprotective… 
Highly Cited
2013
Highly Cited
2013
Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.
Glucagon-like peptide (GLP-1) increases insulin secretion but is rapidly degraded (half-life: 2 min in circulation). GLP-1… 
Highly Cited
2012
Highly Cited
2012
Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo…
Diabet. Med. 29, 1260–1267 (2012) 
Highly Cited
2011
Highly Cited
2011
PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue.
Derived from endocrine pancreatic beta cells, insulinomas express glucagon-like peptide-1 (GLP-1) receptor with high density and… 
Review
2010
Review
2010
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
BackgroundGlucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are… 
Highly Cited
2009
Highly Cited
2009
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Patients with Type 2 diabetes are likely to have or to develop renal impairment, which… 
Highly Cited
2005
Highly Cited
2005
Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes
Aims  Liraglutide (NN2211) is a long‐acting GLP‐1 analogue, with a pharmacokinetic profile suitable for once‐daily administration… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)